Eli Lilly and Company (NYSE:LLY) Trading Down 1.6% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) were down 1.6% during mid-day trading on Monday . The stock traded as low as $978.87 and last traded at $988.76. Approximately 2,011,022 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 3,185,821 shares. The stock had previously closed at $1,004.92.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by strong momentum in Lilly’s obesity portfolio, with recent coverage highlighting surging Mounjaro sales, raised full-year revenue guidance, and the company’s growing position as a key takeover-style growth story.
• Positive Sentiment: Articles on Lilly’s next-generation weight-loss candidate, retatrutide, note promising clinical-trial data that could strengthen the company’s lead in obesity and diabetes if development continues to progress.
• Neutral Sentiment: Lilly also announced it will participate in Bernstein’s 42nd Annual Strategic Decisions Conference on May 28, which could give management another opportunity to reinforce its growth outlook. Article Title
• Negative Sentiment: The biggest drag on the stock is the U.S. Supreme Court’s decision not to hear Lilly’s appeal in a whistleblower Medicaid fraud case, leaving in place a roughly $194 million award and adding a legal overhang for investors. Article Title
• Negative Sentiment: Competitive pressure is also in focus, as reports say Novo Nordisk’s Wegovy pill continues to lead Lilly’s rival obesity offering in prescription tracking, underscoring that Lilly’s growth story still faces meaningful market competition.

Analyst Ratings Changes

Several equities analysts have weighed in on LLY shares. Wolfe Research restated an “outperform” rating and set a $1,325.00 price target on shares of Eli Lilly and Company in a report on Monday, May 4th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company Trading Down 1.6%

The stock has a market capitalization of $931.15 billion, a P/E ratio of 35.12, a P/E/G ratio of 1.09 and a beta of 0.48. The stock’s 50 day moving average price is $939.88 and its 200-day moving average price is $998.21. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $12,976,634,000. Capital Research Global Investors increased its position in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP lifted its holdings in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. lifted its holdings in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. Finally, Fifth Third Bancorp boosted its position in shares of Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.